BB-1701

N/A

Report date: 2025/01/15 14:09:49

Base Information

Drug NameBB-1701
Drug Alias NameBB-1701
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Eribulin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsTubulin beta-1 chain inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin beta-1 chain
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBliss Biopharmaceutical (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBliss Biopharmaceutical (Hangzhou) Co LtdEisai Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksN/A